Immupharma Share Discussion Threads

[opodio] 20/2/2018 08:42

premium being paid

[opodio] 20/2/2018 08:40

I gotta feeling that tonight's gonna be a good night
That tonight's gonna be a good night
That tonight's gonna be a good, good night…

[hamhamham1] 20/2/2018 08:36

spmc. If I said the opposite, can you imagine what kind of attacks I would get here, but hey, so I guess you can try and get some more pound notes on-board your little rocket ship :)
(they make good fuel)

[ballsac] 20/2/2018 08:35

£200.

[miavoce] 20/2/2018 08:32

LOL @ spmc

[spmc] 20/2/2018 08:31

Looking at the charts once the £1.22 resistance is broken next resistance is at £55 then £100 🚀🚀🚀

[opodio] 20/2/2018 08:29

I dreamt this was 370p next week

[opodio] 20/2/2018 08:26

buys pouring in...£2 here we come this week

[ny boy] 20/2/2018 08:24

For sure the share price won’t be staying at current levels as each day goes, closer to phase 3 results. I still reckon results will be out the week commencing 19 March, later that week The Lupus Conference starts 21 March

Tick tock

[spmc] 20/2/2018 08:21

This is flying now, £2 here we come 🙊

[opodio] 20/2/2018 08:20

The investor event will be held on Monday 26th February 2018 in London, EC2 and will commence at 6pm.


SIX DAYS

Tim McCarthy (IMM Chairman) Two Interviews, 18/1/2018:
"I am really excited that in a relatively short period of time, we could have a drug [Lupuzor] on the market which would benefit literally millions of patients across the world for a condition for which they havn't had an effective treatment ever...

...to be a relatively small UK company, sitting here as we do with this late stage product, owning 100% of it, from a commercial perspective that's really exciting as well because this is potentially a multi-billion dollar drug...this is definately going to be a product which will sell in the multi-billion dollars per year...

...we [IMM] are still only valued at £200 - £250 million. In pharmaceutical terms and the prospect of this drug, that is absolutely still very tiny when you consider the potential of this drug...There are a number of discussions going on...so its exciting on a number of fronts."




Maybe the talks are getting hotter!!!!! roll on £19 a share

[che7win] 20/2/2018 08:12

I think too many here are looking at Benlysta when valuing what we have.

Benlysta wasn't deemed efficacious enough to pass NICE in the UK nor did Germany see it's benefits.

It hasn't taken off because of this and it's side effects.

Nor did it work well in African/Americans where Lupus is more common.

Lupuzor meets an unmet need.

[metis20] 20/2/2018 08:10

P3 failure rates - in a set of small molecule P3 failure rate data discussed on the LSE board, half of the failures were due to safety issues. Fortunately IMM have already stated that the P3 trial has not revealed any safety issues. So far as safety is concerned, IMM is in a post P3 situation.

[stealth wealth] 20/2/2018 08:05

Lupuzor will sell at least $5 billion pa.

[stealth wealth] 20/2/2018 07:54

Bermudashorts, if Lupuzor was producing 84% improvement at 6 months there is every chance it will work for everyone or over 90% at beyond 6 months. Also the fact it targets exactly the right point in the immune system where lupus originates.

[hamhamham1] 20/2/2018 07:52

Favio. I live a long way away. Sorry for the boring reason.

[flavio_monteiro] 20/2/2018 07:39

hamhamham1 I am surprised you are not going to the investor evening on monday as a investor in Immupharma.

Its strange you don't have the time for it as you have the time to post on the ADVFN BB very 10 minutes...

[dontshoutatonce] 20/2/2018 07:37

Bermudashorts, thanks for pointing that out. A good clear post.

[lodgeview] 20/2/2018 07:35

bigshort velo said post pIII

[hamhamham1] 20/2/2018 07:29

I am not going to make it to the investor evening. I can hear the cheers from here :)
Anyone who is going and who is interested in the recent £10m placing, maybe these questions are good to ask?

How much of the recent £10m placing will be spent on the 6 months open label extension?

Benlysta has been running a similar open label extension for 5 years now, do IMM plan the same kind of ongoing extensions?

How are IMM planning to spend the remainder of the £10m placing if p3 is good, if its bad or if its a grey result?

How long do IMM expect that money last for each the above outcomes?

[thebigshortfella] 20/2/2018 07:26

Velofrance1 - I am long but what you wrote is not true. Historically, anti-immune drugs have a 62% success rate at the P3 stage. A previous poster posted the statistical findings a while back the same was quoted in Sharewatch’s newsletter tip. Where do you get 90% from? Tx.

[velofrance1] 20/2/2018 07:17

nyboy Thats right post p3 it should be a formality. 90% of drugs at this stage(post p3) get approved. Only a 1/10 chance of failure given the Lupazor story be can be confident!

[metis20] 20/2/2018 06:31

14619 14631 - great posts - many thanks - needed to balance the shorting rubbish appearing recently.

[ny boy] 19/2/2018 23:32

Good post bermudashorts!

Hopefully in a few months we will all be relaxing on a tropical beach wearing bermudashorts too!